Table 1.

Mutation Profiling by Next Generation Sequencing (NGS)

Specimen	Gene	Alteration	VAF	Coverage	Significance
Donor kidneytumor (50% estimated tumor cellularity, 83% donor)
	MSH2	c.1787A > G; p.N596S	3.5%	1576x	Uncertain (germline)
	TERT	Amplification (18.8x)			Gain-of-function
	CDKN2A	Loss (0.25x)			Loss-of-function
	CDKN2B	Loss (0.23x)			Loss-of-function
Recipient lymph node with metastasis (50% estimated tumor cellularity, 8% donor)
	MSH2	c.1787A > G; p.N596S	37%	1552x	Uncertain (germline)
	MSH6	c.116G > A; p.G39E	34%	193x	Uncertain (germline)
	FANCA	c.1772G > A; p.R591Q	41%	3055x	Uncertain (germline)